Considered and Approved standalone and consolidated financial results for quarter ended 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.5 pts more than Nifty Microcap 250 and 7.0 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Deccan Health Care's board, meeting on February 13, 2026 via video conferencing, approved both standalone and consolidated unaudited financial results for the quarter ended December 31, 2025, along with the limited review report by statutory auditors Keyur Shah & Associates (clean report, no qualifications). On a standalone basis, Q3 revenue from operations rose to Rs. 2,303.20 lakhs versus Rs. 2,042.88 lakhs in the same quarter last year, about 12.7% higher. Net profit after tax jumped sharply to Rs. 95.07 lakhs from Rs. 15.57 lakhs, with EPS at Rs. 0.38 versus Rs. 0.07. For the nine months ended December 2025, standalone revenue grew to Rs. 6,890.61 lakhs from Rs. 5,431.07 lakhs (about 27% YoY), and net profit after tax climbed to Rs. 206.29 lakhs from Rs. 106.19 lakhs (about 94% YoY). The company is a single-segment nutraceutical manufacturer; results include contributions from subsidiary Beyoungstore. No investor complaints were pending during the quarter.
For shareholders, the standout feature is the strong profit growth driven by improving margins, even though quarterly revenue growth was moderate. The nine-month trend shows healthy top-line expansion and meaningful bottom-line improvement, which should support positive sentiment on the stock.